On October 4, 2023 Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing immunogenic small molecule approaches in oncology, reported that it will present a poster on lead therapeutic candidate, PT-112, and its early molecular effects culminate in immunogenic cancer cell death (ICD), at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics (Press release, Promontory Therapeutics, OCT 4, 2023, View Source [SID1234635646]). The AACR (Free AACR Whitepaper)-NCI-EORTC "ENA Triple Conference" will be held from October 11-15, 2023 in Boston.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will detail PT-112’s ability to cause ribosomal biogenesis inhibition and organelle stress in cancer cells. PT-112 is currently in Phase 2 clinical trials for metastatic castrate-resistant prostate cancer (mCRPC) and thymic epithelial tumors (TETs).
Poster Session Details
Title: PT-112, a novel immunogenic cell death inducer, causes ribosomal biogenesis inhibition and organelle stress in cancer cells
Poster number: C128
Session: Poster Session C
Session date + time: Saturday, October 14, 12:30 p.m.-4:00 p.m. ET
Session location: Hynes Convention Center, Level 2, Exhibit Hall D
For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com.